Humoral response to p53 in human colorectal tumors: A prospective study of 1,209 patients

International Journal of Cancer

Volumn 94, Issue 6, 2001, Pages 859-863

  Tang, Reiping ^a   Ko, Miao Chen ^a   Wang, Jeng Yi ^a   Changchien, Chung Rong ^b   Chen, Hong Hwa ^b   Chen, Jinn Shiun ^b   Hsu, Kuan Cheng ^b   Chiang, Jy Ming ^b   Hsieh, Ling Ling ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Carcinogenesis; Colorectal cancer; Lymph node metastasis; p53 antibody; Survival

Indexed keywords

ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; COLORECTAL TUMOR; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION FUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; ANTIBODIES; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0035892332     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1541     Document Type: Article

References (38)

1. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer
2. Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma
3. p53 Antibodies in the sera of patients with various types of cancer: A review
4. Mutations in the p53 gene occur in diverse human tumour types
5. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas
6. p53 mutations in colorectal cancer
7. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life
8. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis
9. The p53 tumour suppressor gene
10. A comparison of the biological activities of wild-type and mutant p53
11. Cancer p53, guardian of the genome
12. Mutations in p53 produce a common conformational effect that can be detected with a panel of monoclonal antibodies directed toward the central part of the p53 protein
13. Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: Distribution on primary structure and exposure on protein surface
14. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein
15. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers
16. Circulating p53 antibody in patients with colorectal cancer: Relation to clinicopathologic features and survival
17. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation
18. Humoral immune response against p53 protein in patients with colorectal carcinoma
19. Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer
20. Antibodies against p53 are associated with poor prognosis of colorectal cancer
21. A genetic model for colorectal tumorigenesis
22. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
23. p53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: A comparative study
24. Correlations between p53-protein accumulation, serum antibodies and gene mutation in colorectal cancer
25. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer
26. Characterisation and clinicopathological correlates of serum anti-p53 antibodies in breast and colon cancer
27. Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors
28. Multiple genetic alterations in distal and proximal colorectal cancer
29. Mutations of p53 gene in human colorectal cancer: Distinct frameshifts among populations
30. Allelic loss of chromosome 17p, mutation of the p53 gene, and microsatellite instability in right- and left-sided colorectal cancer
31. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot
32. p53 gene mutation, tumor p53 protein overexpression, and serum p53 autoantibody generation in patients with breast cancer
33. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers
34. Serum p53 antibodies as early markers of lung cancer
35. + T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms
36. The immune system. Second of two parts
37. Quantification of p53 protein in tumor cell lines, breast tissue extracts and serum with time-resolved immunofluorometry
38. p53 protein is absent from the serum of patients with lung cancer